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Introduction: Large cell neuroendocrine carcinoma (LCNEC) is a 
diagnostic challenge for both pathologists and clinicians. We sought to 
determine the signiﬁcance of overexpression of ASCL1 in LCNEC by 
gene expression proﬁling compared to AD. 
Methods: We performed gene expression proﬁling of 100 lung adeno-
carcinoma (AD) and 6 LCNEC of lung for which the diagnosis was 
established based detailed histologic review and immunohistochemistry 
(IHC). We performed quantitative real-time PCR (qRT-PCR) of frozen 
and formalin-ﬁxed, parafﬁn-embedded (FFPE) samples and IHC of 
TMA to evaluate ASCL1 expression in LCNEC. Patients’ clinical data 
was collected from chart. IHC for common neuroendocrine markers 
(synaptophysin, CD56, chromogranin A), Ki67, caspase-3 and p53 was 
examined using TMA. Association between histology and gene expres-
sion, qRT-PCR, or IHC was examined by Fisher exact test, chi-square 
test or Kruskal Wallis test. Patients’ outcome was analyzed by Kaplan 
Meier survival analysis. 
Results: By unsupervised hierarchical clustering of expression data, 
four different subgroups were deﬁned, and most LCNEC (5/6) were 
clustered in the same branch of the dendrogram. Patients in this genetic 
subgroup were older, with heavier smoking history and shorter sur-
vival; tumors were larger, with high proliferation and apoptotic activity 
(labeling index of Ki67 and caspase-3) compared to other subgroups. 
LCNEC itself also showed higher proliferation and apoptotic activ-
ity and shorter survival than AD. Supervised analysis of the gene 
expression data identiﬁed many genes that were strongly differen-
tially expressed between LCNEC and AD. ASCL1, a proneural basic 
helix-loop-helix transcription factor, was highly expressed in LCNEC 
relative to AD. Quantitative RT-PCR analysis of RNA from frozen and 
formalin ﬁxed samples conﬁrmed that ASCL1 expression was signiﬁ-
cantly higher in LCNEC and small cell lung cancer (SCLC) than AD 
and non-neoplastic lung (NL) (p<0.001, Kruskal Wallis test). By IHC, 
diffuse or focal immunoreactivity of ASCL1 was observed in the nuclei 
of most LCNEC (81%) and SCLC cases (73%), although the intensity 
was variable. ASCL1 immunoreactivity showed signiﬁcant correla-
tion with histologic subtype (p<0.001) and was determined to have the 
best discrimination of all IHC assays tested based on receiver operator 
characteristics (AUC, ASCL1= 0.848, KLK11= 0.550, synaptophysin= 
0.817, CD56 = 0.737, chromogranin A = 0.488). In addition, p53 im-
munoreactivity was positive in signiﬁcantly more LCNEC (5/6) than 
AD (11/99) (p<0.001).
Conclusions: We conclude that LCNEC is biologically and clinically 
distinct from AD of the lung and should be distinguished. ASCL1 is a 
useful marker to aid accurate diagnosis of LCNEC.
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Background: Excision repair cross-complementation group 1 
(ERCC1) is an enzyme that functions in the process of nucleotide 
excision repair by removal of DNA adducts induced by cisplatin. In 
non-small cell lung cancer (NSCLC) lack of ERCC1 expression has 
been reported to correlate with beneﬁt from cisplatin-based adjuvant 
chemotherapy. In NSCLC patients who did not receive chemotherapy 
lack of ERCC1 staining correlated with a more favorable prognosis. 
We sought to determine if ERCC1 expression correlated with clinical 
features and survival in both NSCLC and pulmonary neuroendocrine 
tumors including small cell lung carcinoma (SCLC), large cell neuro-
endocrine carcinoma (LCNEC), typical carcinoid (TC) and atypical 
carcinoid (AC).
Study Design: We immunohistochemically stained tissue microar-
rays with 283 NSCLC including 140 adenocarcinomas (ADC) and 
71 squamous cell carcinomas (SCC) as well as 59 SCLC, 40 TC, 26 
AC, and 21 LCNEC using the Neomarker, mouse, clone 8F1 antibody 
to ERCC1. A score for each case was made based on distribution and 
intensity of staining and positive thresholds set according to clinical/
molecular correlations. Followup was available in 230 NSCLC and 133 
NE tumors. Kaplan Meier survival analysis and chi-square statistics 
were made using SPSS v 13.
Result: For NSCLC a high level of ERCC1 staining was seen in 
30/253 cases (11%) with 14/140 (10%) ADC and 16/143 (11.2%) 
squamous carcinomas. Five year survival was signiﬁcantly reduced 
in patients with ERCC1 positive (87%) vs negative (39.8%) tumors 
(p=0.002). This was driven by the ﬁve year survival for adenocarci-
noma that was signiﬁcantly reduced in patients with ERCC1 positive 
(0.83%) vs negative (43.8%) (p=0.002). There was no signiﬁcant dif-
ference in survival by ERCC1 for squamous cell carcinomas. For NE 
tumors, ERCC1 was positive in 5/40 TC (12.5%), 1/26 AC (3.8%) and 
2/21 LCNEC (9.5%) with signiﬁcantly more staining in 16/59 (27.1%) 
of SCLC (p=0.033). No correlations were found with age, sex or sur-
vival in the NE tumors.
Conclusion: Our ﬁnding that patients with ERCC1 positive tumors 
had a signiﬁcantly worse outcome is different from a previous report 
that a control population of patients who did not receive chemotherapy 
who had with ERCC1 positive tumors had a better overall survival than 
patients with ERCC1 negative tumors. Because of the lack of clinical 
information regarding chemotherapy we were not able to address the is-
sue whether ERCC1 correlated with response to chemotherapy or not. 
